Celgene, Elan settle Abraxane case for $78M; Health groups ask Novartis to back off Gleevec patent;

Patents on file

@FiercePharma: AZ's dental unit attracts a slew of suitors. Story | Follow @FiercePharma

> Celgene has agreed to pay Elan $78 million to settle a patent infringement lawsuit over the Celgene breast cancer drug Abraxane. In return, Celgene gets a worldwide license to several of Elan's related patents. Report

> Novartis has been urged to drop its "persistent legal actions" in India regarding patent coverage for its anticancer drug Glivec and a challenge to the country's patent laws over fears the latter could hinder access to medicines. News

Upcoming Webinar

Lifecycle Management Strategies Targeted For Patient Populations with Swallowing Disorders

Hear from industry experts as they discuss life cycle management strategies for patients with swallowing disorders and the overall impact on patient perception. The webinar will include several panel speakers representing different perspectives and case study examples. Save your spot and register today!

> Irish drugmaker Shire said Watson Pharmaceuticals is seeking marketing approval for a new generic version of the attention deficit hyperactivity disorder treatment Adderall XR. Story

> Valeant Pharmaceuticals posted cash earnings and revenue that topped expectations for its first full quarter since combining with Canada's Biovail, sending its shares higher. Item

> Specialty pharmaceutical company Warner Chilcott's Q4 profit marched past market expectations, helped by sales from products acquired from Novartis and Procter & Gamble. Article

> The FDA has teamed up with Georgetown University to do joint research on public health, ethics, bioinformatics and more, and to cooperate on training and continuing education. Report

Biotech News

@FierceBiotech: Pfizer's crizotinib eliminates signs of advanced lymphoma. Report | Follow @FierceBiotech

@JohnCFierce: Coviden, Valeant vet Chuck Bramlage named CEO at Pearl Therapeutics. News | Follow @JohnCFierce 

> Two European cell therapy companies merge. Item

> FDA hands Protalix a CRL for Gaucher's disease drug. News 

> Osage closes lid on $100M war chest for university start-ups. Story

> Lilly neuroscience chief steps down. Report

And Finally... A rising PSA level isn't such a good predictor of prostate cancer after all and can lead to many unnecessary biopsies, says a large new study. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.